WEKO3
アイテム
Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema
http://hdl.handle.net/10069/38746
http://hdl.handle.net/10069/3874681d73cac-05d6-40c4-9483-e9e15fa64bb9
名前 / ファイル | ライセンス | アクション |
---|---|---|
CliOph12_1845.pdf (1.0 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-12-20 | |||||
タイトル | ||||||
タイトル | Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Diabetic macular edema | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Enhanced depth imaging optical coherence tomography | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Kallidinogenase | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Laser speckle flowgraphy | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Tsuiki, Eiko
× Tsuiki, Eiko× Suzuma, Kiyoshi× Matsumoto, Makiko× Mohamed, Yasser Helmy× Kitaoka, Takashi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: This study was designed to investigate the therapeutic effects of oral kallidinogenase medication as an adjuvant therapy in treating patients with diabetic macular edema (DME). Study design: This was a prospective, open-labeled, randomized study. Methods: All patients were given posterior sub-Tenon triamcinolone acetonide (STTA) injection and focal laser treatment session for DME. The patients were subdivided into two groups: 1) those treated with oral kallidinogenase for at least 6 months after local treatment(treated group) and 2) those treated without oral kallidinogenase (untreated group). In this study, best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and chorioretinal blood flow level were measured in 17 patients (19 eyes). Chorioretinal blood flow levels at the disc and macula were measured by laser speckle flowgraphy and evaluated using the mean blur rate (MBR). These data were measured at baseline and at 1, 3, and 6 months after treatment initiation. Results: BCVA at 6 months after treatment significantly improved in treated group (P,0.05).But the mean CRT after treatment significantly decreased in both groups. There was no significant difference in the mean SCT at baseline between the two groups. The mean SCT after treatment in treated group was significantly thinner than that before treatment(P,0.05). Compared to baseline (100%), MBR at the disc and the macula at 6 months after treatment significantly decreased to 84.8% and 86.2%, respectively, in untreated group (P,0.05), though it remained unchanged at 98.7% and 99.7% in treated group.Conclusion: Oral kallidinogenase medication is useful as an adjuvant therapy to enhance the therapeutic effect of STTA in DME patients. |
|||||
書誌情報 |
Clinical Ophthalmology 巻 12, p. 1845-1852, 発行日 2018-12 |
|||||
出版者 | ||||||
出版者 | Dove Medical Press Ltd | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 11775467 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 11775483 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.2147/OPTH.S168420 | |||||
権利 | ||||||
権利情報 | c 2018 Tsuiki et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Clinical Ophthalmology, 12, pp.1845-1852; 2018 |